• Patients successfully treated during a 3-month period with either imipramine hydrochloride pharmacotherapy, cognitive therapy, or combined cognitive-pharmacotherapy were monitored during a 2-year posttreatment follow-up period. Half of the patients treated with pharmacotherapy alone continued to receive study medications for the first year of the follow-up. All other patients discontinued treatment at the end of the acute treatment phase. Patients treated with cognitive therapy (either alone or in combination with medication) evidenced less than half the rate of relapse shown by patients in the medication—on continuation condition, and their rate did not differ from that of patients provided with continuation medication. It appears that providing cognitive therapy during acute treatment prevents relapse. Whether this preventive effect extends to recurrence remains to be determined.
Evans MD, Hollon SD, DeRubeis RJ, et al. Differential Relapse Following Cognitive Therapy and Pharmacotherapy for Depression. Arch Gen Psychiatry. 1992;49(10):802–808. doi:10.1001/archpsyc.1992.01820100046009
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.